£1.4M
The pre-seed round was co-led by Laidlaw Scholars Ventures and APEX Ventures.
CB
CardiaTec Biosciences
CardiaTec Biosciences applies artificial intelligence to multiomic data for cardiovascular drug discovery.
Cambridge, UK—Founded 2021
£1.4MTotal raised
CardiaTec Biosciences develops artificial intelligence platforms to analyse large-scale multiomic data for cardiovascular disease target discovery. The company operates from Cambridge.
Filed accounts
Cash at bank
Members only
Net current assets
Members only
Total assets less current liabilities
Members only
Net assets
Members only
Shareholders' funds
Members only
Fixed assets
Members only
Cash, assets and headcount from CardiaTec Biosciences's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Categories
Founders
Raphael Peralta
CEO
Raphael is the co-founder and chief executive of CardiaTec Biosciences. His background includes venture analysis at Start Codon and consulting for PlaqueTec.
LinkedIn
Thelma Zablocki
COO
Thelma is the co-founder and COO of CardiaTec Biosciences and a board member of the BioIndustry Association. She previously held roles in venture capital and consulting.
LinkedInNH
Namshik Han
CTO
Namshik co-founded CardiaTec Biosciences as CTO and brings academic experience from the University of Cambridge and Yonsei University.
LinkedIn